BLASUBCUTANEOUSSOLUTION
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RELEUKO (filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) indicated for patients experiencing chemotherapy-induced neutropenia and other conditions requiring leukocyte stimulation. It works by binding to G-CSF receptors on hematopoietic cells to promote neutrophil proliferation and differentiation. The drug is administered via subcutaneous injection as a solution.
Peak
Product is at peak commercial stage with moderate competitive pressure (30), indicating stable team size and focus on market defense and operational excellence.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Topefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia
Started Jan 2026
100 enrolled
Preeclampsia
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
Started Apr 2025
18 enrolled
Preeclampsia
Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults
Started Apr 2025
180 enrolled
Healthy Volunteer
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
Started Mar 2025
18 enrolled
Preeclampsia
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
Started Nov 2023
100 enrolled
Breast Neoplasms
Worked on RELEUKO at Kashiv BioSciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.